Immunic, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Immunic, Inc. (IMUX) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $28.40 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2024-05-08
- Immunic, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2024-03-31 was $28.40M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month |
|---|---|
| 2024-03-31 | $28.40M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B |